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Abbreviations used in this article: APC, antigen-presenting cell; CD, cluster of 
differentiation; CL, clodronate liposomes; CM, cerebral malaria; DNA, deoxyribonucleic 
acid; ECM, experimental cerebral malaria; GPI, glycosylphosphatidylinositol; IFN-γ, 
interferon gamma; IL, interleukin; iRBC, infected red blood cell; LPS, lipopolysaccharide; 
LT, lymphotoxin; MCP-1, monocyte chemoattractant protein-1; Myd88, myeloid 
differentiation primary response protein 88; ODN, oligodeoxynucleotide; PAMP, pathogen-
associated molecular pattern; Pb, Plasmodium berghei; rRNA, ribosomal ribonucleic acid; 




Recognition of pathogen-associated molecular patterns (PAMPs) through Toll-like 
receptors (TLRs) plays a pivotal role in first-line pathogen defence. TLRs are likely also 
triggered during a Plasmodium infection in vivo by parasite-derived components. 
However, the contribution of innate responses to liver infection and to the subsequent 
clinical outcome of a blood infection is not well understood. To assess the potential 
effects of enhanced TLR-signalling on Plasmodium infection, we systematically 
examined the effect of agonist-primed immune responses to sporozoite inoculation in 
the P. berghei/ C57Bl/6 murine malaria model. We could identify distinct stage-specific 
effects on the course of infection after stimulation with two out of four TLR-ligands 
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liver that depended on macrophages and the expression of iNOS. These factors have 
previously not been recognised as antigen-independent effector mechanisms against 
Plasmodium liver-stages. Priming with TLR4 and -9 agonists also translated into blood 
stage-specific protection against experimental cerebral malaria (ECM). These insights 
are relevant to the activation of TLR signalling pathways by adjuvant systems of anti-
malaria vaccine strategies. The protective role of TLR4-activation against ECM might 





Malaria, caused by the apicomplexan parasite Plasmodium, continues to be one of the most 
urgent public health problems worldwide (1). Severe forms of malaria, including cerebral 
malaria, mostly affect children and naïve individuals, who have not yet acquired partial anti-
parasite immunity or disease tolerance. In these individuals, non-adaptive immune 
mechanisms are crucial to control the infection, but the host’s immune response is also 
involved in severe immunopathology (2-4). 
 During natural malaria transmission, infective sporozoites are inoculated during blood 
feeding by an infected female Anopheles mosquito. Sporozoites migrate in the skin, enter a 
capillary blood vessel, infect hepatocytes and undergo asexual replication in the liver to form 
merozoites, which are released into the blood stream. These merozoites infect erythrocytes 
for further rounds of schizogony and ultimately form sexual stages that can be re-transmitted 
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clinical signs and complications, pre-erythrocytic stages form a bottleneck in the Plasmodium 
life cycle and are considered clinically and immunologically silent (5, 6). 
Malaria-related morbidity and mortality are mainly attributed to complications of 
infections with P. falciparum, which can cause severe anaemia, respiratory distress, severe 
hypoglycaemia, cerebral malaria or combinations thereof (7). Cerebral malaria (CM) is 
marked by a deterioration of the patient’s neurological status leading to coma. CM is as a 
result of the sequestration of infected red blood cells (iRBC) to the brain microvasculature, a 
dysregulation of pro-inflammatory cytokines, brain swelling, and vascular dysfunction (8). 
As a surrogate experimental model of CM, murine Plasmodium infections resulting in 
experimental cerebral malaria (ECM) are widely used (9). In this model, C57Bl/6 mice are 
infected with P. berghei (Pb; strain ANKA) and develop ataxia, paralysis, seizures, and coma 
6-11 days after infection. This disease model has revealed important pathomechanisms, such 
as dysregulation of the pro-inflammatory cytokines gamma interferon (IFN-γ) (10), tumour 
necrosis factor (TNF) (11) and lymphotoxin (LT) (12) and migration of CD8
+
 T cells to the 
microvasculature of the brain (13, 14).  
Toll-like receptors (TLR) are a conserved group of pattern recognition receptors that 
play pivotal roles in the recognition of pathogen derived components and initiation of innate 
immune signalling pathways (15). Different TLRs have distinct molecular ligand specificities 
to pathogen-associated molecular patterns (PAMPs) that are conserved across species (16). 
TLR2 is activated by components of the bacterial cell wall, such as lipoteichoic acid and 
peptidoglycan (17); TLR3 binds double stranded RNA and can be activated by the synthetic 
analogue polyinosine-polycytidylic acid (poly I:C) (18); lipopolysaccharide (LPS) of gram-
negative bacteria is sensed by TLR4 (19); and TLR9 senses unmethylated CpG motifs in 
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  As ECM has been linked to dysregulation of pro-inflammatory signals, various studies 
have attempted to unravel the role of TLRs and their major downstream signalling molecule 
myeloid differentiation primary response protein 88 (MyD88) in the development of ECM. 
For malaria infections initiated with iRBCs, mice deficient in MyD88 or TLR1, -2, -3, -4, -6, 
-7, or -9 (21) or those triple deficient in TLR2, -4 and -9 (22) were found to be as susceptible 
to ECM as WT mice. In sharp contrast, we, using sporozoite-induced infections, and others, 
using iRBC-induced infections, observed either partial or almost full protection from ECM in 
Pb ANKA-infected mice deficient in MyD88 and partial protection from ECM in mice 
deficient in TLR2, combined TLR2/4, TLR7, TLR9 or combined TLR7/9 (23-25). The latter 
findings are further supported by in vitro studies in P. falciparum, which identified 
glycosylphosphatidylinositol (GPI) and hemozoin as candidate ligands for TLR2 and -9, 
respectively (26, 27), but the correct identification of hemozoin as the malarial TLR9 ligand 
is controversial (28). Moreover, the pharmacological inhibition of TLR9 has been suggested 
as a therapeutic approach to target CM, preventing ECM and increasing survival in the rodent 
model (29). 
 The opposite approach – therapies based on TLR agonists – provides a common 
strategy to target other human diseases, including infectious, malignant, autoimmune and 
allergic diseases (30). However, little is known about the effect of enhanced activation of 
TLRs on the course of malaria infection. Moreover, in a natural transmission setting, the 
clinical course of a malaria infection remains largely unpredictable. Whether co-stimulation 
of the innate immune pathways, e.g. in co-infections with other pathogens, modulates 
Plasmodium infections and disease dynamics remains unsolved. A single study in P. yoelii 
demonstrated that agonists of TLR2, -3, -4 and -9 respectively have a partial inhibitory 
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CpG-motifs, which activate TLR 9, also conferred sterile protection against a low-dose 
inoculum of sporozoites, and the authors attributed the protection to pro-inflammatory 
cytokines and Kupffer cell activity (31). This study also confirmed earlier findings that CpG-
ODNs confer interleukin-12 (IL-12) and interferon-gamma (IFN-γ) dependent sterile 
protection against low-dose infection with P. yoelii sporozoites (32). Similarly, the control of 
murine infections with Toxoplasma gondii, an apicomplexan parasite distantly related to 
Plasmodium, depends on early induction of IL-12 from dendritic cells and IFN-γ produced by 
natural killer (NK) cells, which, in this case, is triggered by mouse-specific TLR11 activation 
(33, 34). 
Antigen-specific immunity to pre-erythrocytic stages is well characterised and 
depends on CD8
+
 memory T cells and IFN-γ expressed by CD4
+
 T cells to induce iNOS and 
NO in hepatocytes to restrict liver-stage development (33). Effector mechanisms of antigen-
independent responses are, in contrast, less well understood. Hepatic macrophages upregulate 
IL-12 in response to a challenge with infectious sporozoites after previous immunization with 
attenuated sporozoites (34), possibly in response to priming with PAMPs. In the absence of 
previous activation, the role of macrophages in liver-stage infection is, however, ambivalent. 
Sporozoite traverse macrophages to facilitate hepatocyte infection and do not get efficiently 
cleared in this process (35). Congruently, viable sporozoites decrease macrophages’ APC 
function and IL-12 expression (34). 
We hypothesised that modulation of Plasmodium infections, achieved by activation of 
Toll-like receptor pathways prior to infection, is characteristic of distinct pathways. 
Intriguingly, using the Pb/C57Bl/6 infection model, we found that specific TLRs and 
associated signalling pathways modulate disease progression and severity by distinguishable 
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of inflections in the immune system and their effect on malaria infection, as well as to 






Application of TLR agonists primes the immunological environment to subsequent Pb 
infection. 
We hypothesised that early innate immune mechanisms are capable of modulating 
Plasmodium infections. We tested this hypothesis in the Pb rodent malaria model. Known 
ligands of TLR2 (peptidoglycan) (17), TLR3 (Poly I:C) (18), TLR4 (LPS) (19) and TLR9 
(ODN 1826, an oligonucleotide containing unmethylated CpG motifs) (20) were injected into 
C57Bl/6 mice to trigger an innate immune response prior to inoculation of Pb sporozoites. 
Additionally, we included a control oligonucleotide with the same sequence as ODN 1826 
but with inverted GpC motifs (ODN1826 Control) not recognised by TLR9 to control for 
potential effects not triggered via this pathway. We also included a group that only received 
PBS.  
In order to distinguish immunomodulatory effects caused by these reagents from the 
response caused by infection with Pb, we first characterised the immune response elicited 20 
h after injection of respective TLR agonists into naïve mice by phenotypic analysis of spleen 
and liver derived antigen-presenting cells (APCs) and lymphocytes (Fig 1A). Injection of 
ODN 1826 upregulated CD86 and CD80 expression on splenic CD11c
+
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upregulated MHC Class II expression on both splenic and liver CD11c
+
; CD80 expression 
was downregulated on liver CD11c
+
 cells (Fig 1B). Injection of LPS upregulated CD86 and 
CD80 expression on splenic CD11c
+
 cells, and upregulated MHC Class II expression on liver 
CD11c
+
; MHC II expression was downregulated on splenic CD11c
+
 cells, as well as CD80 
expression on liver CD11c
+
 cells. Injection of Poly I:C upregulated CD86, CD80 and MHC 
Class II expression on splenic CD11c
+
 cells and MHC Class II expression on liver CD11c
+
 
cells, CD80 expression on liver CD11c
+
 cells was downregulated. Peptidoglycan only 
upregulated CD80 expression on splenic CD11c
+
 cells. Injection of ODN1826, LPS and Poly 
I:C upregulated CD86 expression on splenic F4/80
+
 cells (macrophages); injection of Poly 
I:C upregulated CD80 expression on these cells. Injection of ODN1826 upregulated CD86 
and MHC Class II expression on liver F4/80
+
 cells; LPS upregulated CD86
+
 expression on 
these cells. Injection of peptidoglycan and ODN1826 Control barely impacted the 




 cells. Based on the upregulation of 
CD69, ODN 1826, LPS and poly I:C are potent activators of splenic and liver CD4
+
 T cells, 
CD8
+








) cells.  
Next, we assessed the serum levels of the pro-inflammatory cytokines IFN-γ, TNF, 
IL-6 and IL-12p70, as well as the anti-inflammatory IL-10 and the chemokine monocyte 
chemotactic/chemoattractant protein 1 (MCP-1), 20 h after injection of respective TLR 
agonists into naïve mice (Fig 1C). ODN 1826 application led to significantly elevated levels 
of IFN-γ (P=0.032), IL-6 (P=0.021), IL-12 (P=0.008), MCP-1 (P=0.008) TNF (P=0.012) and 
IL-10 (P=0.008). LPS administration significantly induced IL-6 (P=0.021). Injection of poly 
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Together, application of TLR agonists, particularly ODN1826, leads to distinct 
modulations of the immunological environment, as exemplified by changes in the phenotypes 
of splenic and liver leucocytes and serum cytokine levels that will be encountered by an 
incoming pathogen.  
 
Activation of TLR9 pathway modulates Pb liver stage development.  
After characterisation of the immunological responses to pre-stimulation, we compared the 
capacity of the distinct TLR to elicit an innate immune response against pre-erythrocytic 
stages of Plasmodium. We focussed on the TLR3-, TLR4- or TLR9-agonists given the poor 
responses elicited by peptidoglycan in our initial experiments (Fig 1). We treated mice with 
poly I:C, LPS and ODN 1826, and 20 h later, infected them with 10
4
 Pb sporozoites (Fig 2A); 
parasite loads in the liver were assessed by the quantification of the relative amount of 
parasite 18S rRNA 42 hours after infection. Control groups included those that received PBS 
and OD1826 Control. Stimulation with ODN 1826 reduced the hepatic parasite load by 89% 
of the average amount found in the PBS-treated control group (P=0.0007) (Fig 2B). 
Stimulation with Poly I:C, LPS and ODN1826 Control had no effect on hepatic parasite 
burden (P>0.05). 
We also initially confirmed whether the reduction caused by ODN 1826 indeed 
depends on the innate signalling pathway described for TLR9 (36, 37), by pre-treating and 
infecting WT C57Bl/6 mice and mice deficient for the myeloid differentiation factor 88 
(MyD88) in side-by-side comparison (Suppl Fig S1). Consistent with our earlier results, 
stimulation with the ODN1826 led to a reduction by 88% in WT controls (P=0.0005), whilst 
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(P=0.5). Moreover, there was no difference of the parasite 18S rRNA levels between 
untreated WT mice and MyD88
-/-
 mice that had received ODN 1826 or PBS (both P>0.05). 
 
Activation of TLR9 pathway does not affect gliding motility of Plasmodium sporozoites.  
In order to further substantiate our hypothesis that activation of the innate immune 
system was responsible for the reduction of the hepatic parasite load in vivo, we tested in 
vitro if direct stimulation of hepatocytes can autonomously limit parasite development. We 
pre-stimulated primary mouse hepatocytes for 24h with Poly I:C, LPS and ODN 1826 and 
infected them with Pb sporozoites. Compared to pre-treatment with sterile culture medium or 
ODN 1826 Control, we did not observe any morphological or quantitative difference in the 
formation of exo-erythrocytic forms (EEF; Fig 3A and B).  
Reports that CpG oligonucleotides are able to inhibit Plasmodium gliding motility in 
vitro (38) also prompted us to consider that this a possible explanation for the delayed 
development of pre-erythrocytic stages. Therefore, we tested if LPS and ODN 1826 (versus 
ODN1826 Control) – two agonists that either affected EEF development in vivo (Fig 2) or 
subsequent blood stage infection (Fig 6) – inhibited sporozoite motility, which then impacts 
the development of EEFs in vitro. Using immunofluorescence microscopy to visualise trails 
of circumsporozoite protein (CSP) shed by the parasite, addition of 100µM or 20µM ODN 
1826 – doses exceeding concentration that the parasite would reasonably encounter in vivo 
after i.v. administration – reduced the number of trains observed (Fig 3C); motile parasites 
were reduced by 83% and 81%, respectively (data not shown). Similarly, addition of the 
same concentrations of ODN 1826 control led to comparable reduction in the trails observed. 
Because we did not observe any difference between ODN 1826 and the ODN 1826 Control, it 
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the hepatic parasite load. LPS treatment did not substantially impact sporozoite motility in 
vitro (Fig 3C).  
 
Inhibition of Pb pre-erythrocytic stages depends on innate activation and IFN-. 
To further analyse the contribution of distinct cytokines to the inhibition of Pb pre-
erythrocytic stages in the specific setting of the liver, we measured the amounts of transcripts 
of type I interferon, IFN-γ, IL-12p35 and p40 and IL-10 42 h after infection of pre-treated 
mice (Suppl Fig S2). IFN-γ transcripts were upregulated 240-fold in the group that had 
received ODN 1826, whilst all other ligands did not induce such a robust response. Similar to 
IFN-γ, we found a 15-fold induction of IL-12 that was restricted to ODN 1826-treated mice. 
We quantified the abundance of transcripts of IFN-α (by assessing a consensus region of 
IFN–α 1, -2, -5, -6, -7, -9, -11, -12 and -13) and of IFN-β that synergise with IL-12 to drive 
cell mediated immune responses (39). These interferons have, for instance, been implicated 
in the regulation of IFN-γ and Nitric Oxide Synthase 2 (iNOS) as central players in the early 
response against the protozoan parasite Leishmania major (40). Whilst we did not observe a 
differential regulation of IFN-α, we found an upregulation of IFN-β by approximately 35-fold 
in mice that had received ODN 1826 prior to infection. 
These observations of differentially regulated cytokines are consistent with a known 
role of IL-12 to activate NK cells (41, 42) and TH1 cells to produce IFN-γ (42) or IFN-γ and 
IL-10 simultaneously (43). Using RAG1
-/-
 mice, which are deficient in T (and B) cells, we 
showed that the innate response elicited by ODN 1826 was not sufficient to significantly 
reduce the hepatic parasite load (P=0.059; Fig 4), suggesting a role for T cell activation in 
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with ODN 1826. Mice that lacked a functional IFN-γ receptor were unable to significantly 
reduce the parasite load (P=0.88; Fig 4). 
 
Inhibition of Pb pre-erythrocytic stages depends on macrophage activation. 
Having assessed the importance of IFN-γ induction, we eventually examined the presumed 
effector cells by broad depletion of mononuclear phagocytes with clodronate-liposomes (CL). 
CL were injected i.p. two days prior to ODN 1826 application (Fig 5A). Depletion efficacy 
was controlled by flow cytometry analysis of peritoneal, splenic and hepatic leucocytes, 




 population after 48h in animals that received the 
depletion regimen alongside the experimental animals (Suppl Fig S3).  
We compared four groups of mice, which either received PBS, PBS/ODN, CL or 
CL/ODN (Fig 5B). Depletion of mononuclear phagocytes ablated the ability of TLR9 
activation to induce a reduction of the parasite load in the liver. We observed no significant 
differences between mice that had received CL plus ODN 1826 and untreated controls or 
controls that had received CL only (P>0.05). Comparison of untreated mice with mice that 
had received ODN 1826 but no CL revealed a significant difference (P=0.016), supporting 
the notion of complete reversion of the anti-parasitic effect by CL (Fig. 5B).  
 The observation that liver stage inhibition is reversed by broad depletion of 
phagocytes was consistent with differential alteration of local iNOS transcription (Fig 5C). In 
parallel to the determination of hepatic parasite burden, we tested for local iNOS expression 
levels by quantitative real-time PCR. Pre-stimulation with ODN 1826 alone led to >10-fold 
upregulation compared to naïve mice, but we did not observe a significant difference in mice 
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does not upregulate iNOS transcription. Strikingly, CL pre-treatment largely reduced the 
ODN 1826 -mediated iNOS overexpression to a 3-fold increase only (Fig 5C). 
 Together, these data establish that the anti-liver stage effects of TLR9 activation can 
be attributed to increased IFN-γ release by innate and adaptive sources supporting the 
effector function of hepatic macrophages. 
 
TLR activation impact clinical outcome of sporozoite-induced blood stage infection.  
To assess whether activation of TLR-pathways prior to inoculation of sporozoites not only 
affects the pre-erythrocytic stages of the Pb life cycle but also the subsequent blood-stage 
infection, we monitored the time to blood-stage infection, the development of parasitaemia, 
survival, and ECM development in groups of mice treated with ODN 1826, Poly I:C and LPS 
compared to ODN 1826 control or PBS (Fig 6A). We detected blood stage parasites in mice 
in the control groups on three to four days post-infection (Fig 6B). In mice treated with ODN 
1826, in contrast, blood-stage infections were only detectable significantly later and appeared 
between days 5 and 7 post-infection (P=0.0034) (Fig 6B,C). Parasitaemia levels were 
significantly lower in the ODN 1826-treated animals as compared to the PBS group on days 5 
(P=0.0043), 6 (P=0.0022) and 7 (P=0.0043) of the observation period. The apparently low 
parasitaemia observed in the LPS group compared to the PBS group did not reach 
significance. Application of Poly I:C or peptidoglycan did not significantly affect the time to 
patency. Despite a longer prepatent period in ODN 1826-treated mice, the rate at which 
parasitaemia increased was similar in all groups once a blood-stage infection had been 
established (Fig 6C).  
PBS or ODN 1826 control-treated C57Bl/6 mice developed classical neurological 
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received ODN 1826 correlated with a significantly different survival curve from the control 
groups (P=0.0008, log-rank test) (Fig 6D), and majority of the animals were protected against 
ECM (Fig 6E). Notably, the survival curve for LPS-treated mice was also significantly 
different from the control groups (P=0.0008), and the majority of the animals were also 
protected against ECM. Mice that did not succumb to ECM were not protected from 
developing anaemia and high levels of parasitaemia. 
 
Cytokine patterns after TLR activation and sporozoite-induced blood stage infection 
We further assessed the serum levels of IFN-γ, TNF, IL-10, IL-6, IL-12p70 and MCP-1 at 0h 
(time of infection; as Fig 1D), 24 h and 5 days after injection of sporozoites into pre-
stimulated mice. C57Bl/6 mice that developed ECM were shown to exhibit high levels of 
serum IFN-γ, TNF and MCP-1 prior to the onset of neurological signs (10, 11, 44). 
Consistent with this observation, PBS- and ODN 1826 Control-treated mice had significant 
increases in these cytokines on day 5 after sporozoite infection (Fig 7). In contrast, 
sporozoite-infected mice pre-treated with ODN 1826 or LPS had an almost inverted cytokine 
pattern. Pre-treatment with ODN1826 initiated a robust secretion of IFN- γ at the time of 
infection and 24 hours later. At both time points, average levels observed were >8-fold higher 
than in PBS-treated mice. Notably, pre-treatment with ODN 1826 prevented the characteristic 
peak of IFN-γ levels on day 5 after infection; serum IFN-γ levels were about 15x lower as 
compared to the control group when it developed ECM. Serum MCP-1 concentrations in 
ODN1826-treated mice increased by more than 100x at the time of infection. One day later, 
MCP-1 concentrations decreased, and it was only slightly elevated on day 5 after infection. 
No induction of TNF could be detected after administration of ODN 1826. IL-6, IL-10 and 
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ODN1826, pre-treatment with LPS led to low serum levels of IFN-γ, MCP-1 and TNF on 
day five after infection, which correlated with the observed protection against ECM. 
Activation of the TLR3 pathway did not prevent progression to ECM and was associated with 
an increase in serum IFN-, MCP-1 and TNF levels before manifestation of clinical signs.  
 
TLR9 activation impacts clinical outcome following iRBC-initiated infection.  
We have shown that stimulation with ODN 1826 significantly reduced the hepatic parasite 
load following sporozoite infection compared to the control group (Fig 5B), and this 
eventually led to delayed prepatency and protection against ECM (Fig 6). We wanted to 
explore further whether there is an association between the effects of TLR9 activation on 
liver stage development and the reduction in the progression of infected mice to ECM. For 
this purpose, we evaluated initially the effect of TLR9 activation on iRBC-initiated infection, 
bypassing the liver stage. We monitored the development of parasitaemia, survival and ECM 
development in groups of mice treated with ODN1826 or PBS, and infected with iRBCs 20h 
later (Fig 8A). We observed blood stage parasites in all mice in the control group on day 
three post-infection (Fig 8B). After treatment with ODN1826, blood stage parasites were 
detectable four days after infection in most animals. Parasitaemia levels were significantly 
lower in the ODN 1826-treated animals as compared to the PBS group on days 4 (P=0.0294), 
6 (P=0.0284) and 7 (P=0.0286) of the observation period. Finally, treatment with ODN 1826 
conferred significantly longer survival (Fig 8D; P=0.008) and protection against ECM 













We systematically assessed the capacity of distinct TLR signalling pathways to influence a 
subsequent Plasmodium infection in the PbANKA / C57Bl/6 infection model. Infections 
were initiated with sporozoites in order to not bypass the obligate liver-stage phases of the 
life cycle when infections are started with iRBCs. Monitoring the course of infection and 
profiling the cytokine response during host infection, we found that (i) activation of TLR9 
has an inhibitory effect on Pb pre-erythrocytic stages, and (ii) the observed inhibition of 
Plasmodium pre-erythrocytic stages was associated with the induction of a pro-inflammatory 
environment as exemplified by an early increase of IL-12, IFN-γ, and MCP-1 serum levels 
and expression. When we assessed underlying mechanisms, we observed that (iii) the 





 macrophages with clodronate-liposomes completely reverses the effect and 
limits local iNOS overexpression. We also found that (v) while activation of TLR3 did not 
show any effect against subsequent blood-stage infections, stimulation of TLR4 or -9 in 
susceptible C57Bl/6 mice prior to challenge with Pb ANKA sporozoites significantly reduces 
the occurrence of ECM; (vi) such protection is associated with suppression of IFN-γ, TNF 
and MCP-1 responses at day five after infection, before the onset of symptoms. Initial 
experiments showed that (vii) TLR9 has an inhibitory effect on iRBC-induced infections.  
Previous work has established that live homologous or heterologous pathogen 
infections, that is by Plasmodium sporozoites (45, 46) or enveloped insect baculovirus (47), 
restrict consecutive Plasmodium liver stage development. This inhibitory effect could be 
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interferon IFN-γ were identified as critical signatures (47). In the present study, we could 
show that robust Plasmodium liver stage inhibition can be specifically achieved by prior 
activation with the TLR9 agonist CpG-DNA, but none of the other agonists. We demonstrate 
that this trigger of innate defence pathways can occur in the absence of live pathogens and is 
critically mediated by macrophages, providing a plausible explanation for the previous 
observation that lys-M expressing cells are recruited to the liver after induction of interferon 
signalling (48). 
When stimulating C57Bl/6 mice with ODN1826 prior to challenge with Pb ANKA we 
observed the capacity of the TLR9 pathway to modulate malaria progression. Inhibition of 
liver-stage development of Pb led to a delay in blood-stage patency, and we report a 
significantly reduced number of animals that progressed to ECM. Whilst low liver stage 
burden is usually associated with a delay in blood-stage patency, it is conceivable that the 
inflammatory environment – as exemplified by increase in serum levels of IL-12, IFN-γ and 
MCP-1 –  induced following TLR9 activation can also impact blood stages as they egress out 
of the liver. Nonetheless, our findings that activation of TLR9 has an inhibitory effect on Pb 
pre-erythrocytic stages, are consistent with observations that an altered, often inflammatory, 
pre-erythrocytic or early immune response at day 0-1 may change later host immune 
responses at days 5 and thereby reduce the incidence of ECM (49). When we induced a TLR-
mediated immune response prior to infection with Pb iRBCs, which bypasses the liver stages 
of infection, animals had lower parasitaemia and were completely protected against ECM. 
This suggests common TLR9-induced effector mechanisms affecting both liver and blood 
stages of infection. Given the limited scope of our experiments with iRBCs, further work is 
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Based on previous reports that CpG ODNs impair sporozoite locomotion by negative 
charges (38), we tested if direct inhibition of parasites, which bypasses immune signalling via 
TLR9, plays a principal role in reducing and delaying pre-erythrocytic stages. While we 
could confirm that CpG ODNs inhibit sporozoite gliding-motility, we observed that non-
TLR9 binding oligonucleotides have an identical effect on sporozoites in vitro, but have no 
effect in the course of murine infections. Additionally, we observed in vitro that priming of 
primary mouse hepatocytes, which have been shown to express TLR1 through -9 (50), with 
ODN 1826, LPS, poly I:C or ODN 1826 control is not sufficient to render them less 
susceptible to infection with sporozoites. Thus, we conclude that ODN 1826 impairs 
development of Pb pre-erythrocytic stages via the TLR9 immune signalling pathway, 
involving cells other than hepatocytes. By priming and infecting mice deficient in the 
common TLR adaptor molecule MyD88, we corroborated that an undisrupted TLR9 
signalling pathway is crucial to target Pb liver-stages with ODN 1826 in vivo.  
Intriguingly, we observed that ODN 1826 elicits a cytokine response very similar to a 
well-known cross-regulatory signalling pathway. Early secretion of IL-12 is known to prompt 
T cells and NK cells to produce IFN-γ to activate phagocytic effector cells to counter 
intracellular infection (41). Activated macrophages in turn produce IL-12 to maintain IFN-γ 
secretion by T cells and NK cells and thus feed-forward the immune response (41, 42). We 





C57Bl/6 mice. After ODN 1826 stimulation, sporozoite-infected RAG1
-/- 
mice and IFNGR1 
-
/- 
mice, were unable to significantly reduce the parasite load in the liver. We concluded that 
(i) IFN-γ is central to the reduction of liver stages via the TLR9 pathway (ii) sources of IFN-γ 
could include T and NK cells for the observed reduction; and that (iii) the effect is stronger in 
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Based on these findings, we hypothesised that activated macrophages are the primary 
effector cell to mediate Pb inhibition. Depletion of mononuclear phagocytes with CL cells led 
to a complete reversion of the effect of ODN 1826 and a parasite load in the livers, which 
was comparable to untreated animals. In accordance with this mechanism, which had not yet 
been implicated in anti-Plasmodium liver stage activity, we observed that transcription of 
inducible Nitric Oxide Synthase 2 (iNOS) was locally upregulated in the livers of ODN1826-
treated mice. iNOS catalyses the synthesis of the effector molecule NO from L-arginine in 
response to pathogens in an IFN-γ-dependent fashion (51, 52), and NO is considered a major 
effector mechanism of host defence against Plasmodium in the vector A. stephensi (53). In 
good accordance, the amount of iNOS transcripts was significantly reduced in the livers of 
mice depleted of F4/80+/CD11b
+
 cells. Reduction was, however, not complete, pointing 
towards iNOS induction in cells, which are not targeted by CL, such as neutrophils (54). 
Curiously, and in contrast to earlier studies with the cognate pathogen P. yoelii (55), 
treatment with CL did not lead to enhanced proliferation of liver-stages.  
We demonstrate for the first time that priming with sub-lethal doses of LPS 
significantly reduces ECM-related mortality in susceptible C57Bl/6 mice after infection with 
Pb ANKA. Because we did neither observe any inhibition of liver stage development nor 
impaired parasite growth during subsequent blood-stage infection, we conclude that LPS 
modulation of the response to Pb infections primarily interferes with Pb-induced 
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injection, however, regression to very low levels of IFN-γ, TNF and MCP-1 appear to occur, 
and the dysregulation of these cytokines, characteristic of progression to ECM, was 
restrained. This observation resembles the hypo-responsiveness of LPS-primed murine and 
human macrophages to a second challenge with LPS, a condition termed LPS tolerance, 
which is known to interfere with TLR4 signalling in multiple ways (56). Remarkably, a 
previous investigation found malaria infections in humans and mice to inversely induce 
hyper-responsiveness to LPS via TLR9-dependent TLR4 over-expression (57). This 
ultimately led to increased mortality by sub-lethal doses of LPS in the mouse model. By 
analogy, we assume that LPS stimulation ablates ECM by a pleiotropic effect, caused by 
interference with downstream signalling of TLR4. Supporting this hypothesis, TLR4
-/-
 mice 
have been described to succumb to ECM similar to WT mice (21, 58).  
 Interestingly, the effect of TLR4 and -9 activation on ECM resembles observations in 
the context of experimental whole-organism vaccine strategies that altered immune responses 
during the first two days after PbANKA infection paradoxically cause reduced inflammation 
and cerebral pathology five to eight days post-infection (49, 59-62). In contrast, our 
observation that TLR9 activation prevents ECM irrespective of the route of infection is 
counterintuitive to the recent report that depletion of γδ T cells and a liver stage-directed IFN-
γ response are associated with protection against ECM following sporozoite but not iRBC 
infection (63). However, the exact mechanism by which LPS and CpG DNA prevent 
progression to ECM and its potential relevance, e.g. in a bacteria/Plasmodium co-infection 
model remains elusive and the scope of further studies.  
Our findings put into perspective the common perception that TLR pathways are 
primarily involved in malaria-related immunopathology by demonstrating for the first time 
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administration of the anti-inflammatory corticoid dexamethasone has been proven to be no 
more effective than placebo or even deleterious in adjunct therapy of cerebral malaria (64, 
65), a more profound understanding of the role of innate immune signalling in severe malaria 
is warranted to rationally develop adjuvant care to maximize treatment efficacy against the 
severest form of clinical malaria. Likewise, the identification of innate immune signalling and 
effector mechanisms that inhibit Plasmodium liver-stage development has important 
implications for interventions that target this bottleneck in the Plasmodium life cycle. To 
date, only experimental whole organism pre-erythrocytic vaccines confer reliable sterile 
protection against malaria, non-human primates and humans (6). Thus, a deeper 
understanding of innate immune responses against this stage provides means to rationally 
choose and develop effective adjuvants to improve the antigen-specific immunogenicity of 
potential subunit vaccines.  
 
 
Material and Methods 
Animals 
Female C57Bl/6AnNCr mice (6-10 weeks old) were purchased from Charles River 
Laboratories. Mice deficient in MyD88 (obtained from S. Akira (66)), RAG1 or IFNGR1 in 
the C57Bl/6 background were bred in a pathogen-free animal facility at the Max-Planck-
Institute for Infection Biology and have been backcrossed for at least 10 generations.  
 
Pb ANKA infection  
Pb ANKA parasites, which originate from clone 15cy1 that has been engineered to express 
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and Anopheles stephensi mosquitoes. Groups of C57Bl/6 mice were inoculated by 
intravenous (i.v.) injection with 10
4
 sporozoites, which were freshly purified from mosquito 
salivary glands. C57Bl/6 mice that had been inoculated with Pb parasites were observed daily 
for the clinical signs of experimental cerebral malaria (ECM), which was defined by the 
sudden onset of ataxia, paralysis, convulsion or coma (9). Manifestation of ECM signs served 
as the ethical endpoint criterion for culling affected animals. Infected mice that did not 
develop ECM until day 18 after infection were considered resistant and culled in order to 
avoid suffering from high parasitaemia and severe anaemia.  
 
Innate immune modulators and pre-treatment 
The following agonists were injected intraperitoneally (i.p.) in a total volume of 200μl saline: 
ODN 1826 (20nmol/mouse; Eurofins MWG Operon), Lipopolysaccharide (LPS) from E. coli 
O127:B8 (50μg/mouse; Sigma), polyinosinic-polycytidylic acid (Poly I:C; 200μg/mouse; 
Sigma), or peptidoglycan from B. subtilis (50μg/mouse; Sigma). We included a control 
oligonucleotide with inverted CpG motifs without affinity to TLR9 (20nmol/mouse; Eurofins 
MWG Operon) and used 1x PBS (Gibco) as the control for all other agents. All animals were 
monitored after inoculation for pain, distress or local complications at the injection site. 
 
Phenotypic analysis of liver and spleen derived APC and T Cells 
Mice were sacrificed at indicated time points post-infection, livers were perfused with 1x 
PBS to remove contaminating intravascular leukocytes, and spleens and livers were removed. 
Single-cell suspensions from spleens and livers were prepared by homogenizing the organs 
through a 100-mm cell strainer (BD Biosciences). Leukocytes from liver samples were 
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cells were removed from all samples using BD RBC lysis buffer (BD Biosciences), and live 
cells were quantified using a hemocytometer and trypan blue staining. Phenotypic 
characterization of cell populations was performed by surface staining according to standard 
protocols. Antibodies for cell surface staining were obtained from eBiosciences, BD 
Biosciences and the German Rheumatism Research Center: anti-mouse CD3 (17A2); anti-
mouse CD4 (GK1.5); anti-mouse CD8 (53.6-7), anti-mouse CD11c (N418); anti-mouse 
CD49b (DX5); anti-mouse CD69 (H1.2F3); anti-mouse CD80 (16-10A1); anti-mouse CD86 
(GL-1); anti-mouse F4/80 (BM8); and anti-mouse MHCII (M5/114.15.2). For flow cytometry 
quantifications, the following gating strategy on red cell lysed samples was applied: First, the 
lymphoycte population was identified in a side scatter (SSC) vs. forward scatter (FSC) 
density plot; next, the respective percentages of cell populations were determined using 
different gating methods applied to CD3high cells. Data was acquired by flow cytometry 
using an LSRFortessa or LSRII (BD) and analysed using Flowjo9.5.2 (Tree Star, Inc.). For 
this, we have adhered to the ‘Guidelines for the use of flow cytometry and cell sorting in 
immunological studies’ (68).  
 
Cell culture 
Murine hepatocytes were purified as described elsewhere (69). Briefly, a single lobe of 
mouse liver was enzymatically digested and parenchymal cells were suspended in 
supplemented Williams E medium. After removal of debris on a 60% isotonic Percoll 
gradient (GE Healthcare) live cells were cultured at 37 °C in 4% CO2 in William's E medium. 
10
5
 primary hepatocytes were plates in 8-chamber slides (Nunc) and incubated with TLR 
ligands for at least 24 h before infection with 10
4
 Pb ANKA sporozoites. Prior to infection, 
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to remove immunostimulants in the supernatant. Sporozoites and hepatocytes were incubated 
for 2 h at room temperature. Cultures were washed again with HBSS and incubated until the 
indicated time points. After fixation with ice-cold methanol, cultures were stained using a 
primary mouse monoclonal antibody against Pb heat shock protein 70 (HSP70) (70). Exo-
erythrocytic form (EEF) formation was assessed by comparison of the sizes of the parasites 
and by quantification of the absolute number of parasites per slide. 
 
Sporozoite gliding assay 
8-well glass slides were pre-coated with BSA. 3,000 sporozoites in RPMI medium, 
supplemented with indicated immunostimulants, were deposited in each well and incubated at 
37 °C for 1 h. The slides were washed and trail deposits were fixed with 4% 
paraformaldehyde for 15 min. Trails were labelled using polyclonal mouse anti-PbCSP 
antibodies and a secondary rat anti-mouse antibody conjugated to Alexa Fluor® 647 and 
visualized by fluorescence microscopy. 
 
Serum cytokine measurement 
Serum samples for in vivo measurement of cytokines were prepared from heparinized blood 
from naïve and infected mice. Cytokines were quantified with the mouse inflammation 
cytometric bead array kit (BD Bioscience) according to the manufacturer’s instructions on a 
LSR II cell analyser (BD Bioscience). Raw data were analysed with FlowJo software (Tree 
Star). 
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RNA was extracted from homogenized mouse livers using the RNeasy kit (Qiagen) and 
treated with DNase I (Ambion). cDNA was synthesized using the RETROscript kit 
(Ambion). We used SYBR green I Master Mix (Applied Biosystems) for quantitative RT-
PCR on a StepOne Plus real-time PCR system (Applied Biosystems). Genes of interest were 
amplified along with the murine housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) in a total volume of 25 µl in 96-well plates (Applied Biosystems). 
Contamination with genomic DNA was excluded by amplification of a non-transcribed target 
sequence in the CD4 promoter. Oligonucleotide primers (Eurofins MWG Operon) are listed 
in Suppl Table S1. Primers for interferons, IL-10 and IL-12p35/40 as well as the CD4 
promoter have been published previously (71). 
 
Clodronate-liposomes 
Clodronate liposomes (CL) were prepared as described elsewhere (54). Briefly, an emulsion 
of phosphatidylcholin (Sigma) and cholesterol (Sigma) in chloroform was vacuum 
evaporated. Under inert conditions a suspension of clodronate (Sigma) was added and 
encapsulated in multilamellar vesicles by gentle shaking of the reaction vessel. CL were 
washed with sterile PBS and resuspended in the same buffer solution. We injected 0.1 ml of 
CL suspension i.p. for depletion experiments. 
 
Statistical analysis 
The statistical significance of differences between groups was tested with the Mann-Whitney 
non-parametric test . Kaplan-Meier curves were compared with the Log-rank test (Mantel-
Cox). A P-value <0.05 was considered to indicate a significant difference. All statistical 
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(A) Flowchart of experimental procedures. Mice were stimulated with TLR ligands, and 20 
hours later, hepatic and splenic leucocytes were analysed. (B,C) Activation of (B) APCs and 
(C) lymphocytes after treatment with Poly I:C, LPS, ODN 1826 or peptidoglycan (n=4 per 
group each). MFI, mean fluorescence intensity. Error bars indicate SEM. Differences in MFI 
were analysed by the Mann Whitney test to compare TLR agonists to PBS. Data are 
representative of two similar independent experiments. (D) Cytokine concentrations 20h after 
injection of activators of innate immune pathways. PBS (black), ODN 1826 (green) or the 
ODN 1826 Control (cyan) polynucleotide, LPS (yellow), poly I:C (red) or peptidoglycan 
(violet). Shown are mean values (+SEM) for each group (n=5 per group, except for ODN 
1826 control, n=4). Data are representative of at least two similar independent experiments. 
(B-D). *p<0.05; ** p<0.01 (Mann-Whitney). 
 
 
Figure 2. Activation of TLR9 pathway modulates Pb liver stage development.  
(A) Flow-chart of experimental procedures. Mice were pre-stimulated with PBS (black), 
ODN 1826 (green) or the ODN 1826 Control (cyan) polynucleotide, LPS (yellow), or poly 
I:C (red), infected with 10
4
 Pb sporozoites i.v., and analysed for hepatic parasite load. (B) 
Expression levels of Pb18S rRNA as a surrogate of the hepatic parasite load 42h after 
infection with 10
4
 Pb sporozoites. Values are expressed as the percentage of the mean value 
for the PBS control group (PBS, n=10; ODN 1826 control, n=4; ODN 1826, LPS and Poly 
I:C, n=5 per group). Data shown are representative of two independent experiments. Bars 
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Figure 3. Effect of TLR agonists on Pb liver stage development in and sporozoite gliding 
motility in vitro.  
(A) Development of exo-erythrocytic forms (EEFs). Primary mouse hepatocytes were 
incubated for 24h with 2µM ODN1826 Control, 2µM ODN1826, 10µg/ml LPS or 100µg/ml 
poly I:C and infected with 10
4
 Pb sporozoites. Controls were left untreated. Shown are 
representative images of EEFs at 24h, 48h, and 69h after sporozoite infection. (B) 
Quantification of EEF development in pre-stimulated primary hepatocytes. Mean values 
(+SEM) of triplicate samples are indicated. A,B, data are representative of two similar 
independent experiments. (C) Fluorescent microscopy images of Pb sporozoites and gliding 
trails after incubation with TLR ligands. TLR agonist and concentration are indicated. Each 
row shows two representative parasites at two different concentrations. Representative 
images from two similar independent experiments are displayed. 
 
Figure 4. Mechanisms of reduction of hepatic parasite load following TL9 stimulation. 
C57Bl/6 WT (n=14), RAG1-/- (n=11) and IFNGR1-/- (n=13) mice were either treated with 
PBS or ODN 1826 20 h prior to i.p. infection with 10
4
 Pb sporozoites. The hepatic parasite 
load was measured with qRT-PCR 42h later. Data points represent individual animals. 
Cumulative data from three independent experiments. Bars indicate mean hepatic parasite 
load (±SEM). ns, not significant. *** p < 0.001 (Mann-Whitney). 
 
 
Figure 5. Anti-parasitic immune mechanisms induced by TLR9 activation depend on 
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(A) Flow chart of macrophage depletion experiments. Mice were injected i.p. with 0.1ml of 
CL 68h before infection, pre-stimulated with PBS or ODN 1826 two days later and infected 
with 10
4
 Pb sporozoites i.v. another 20h later. After 42h the hepatic parasite load was 
assessed. (B) Parasite load in mice treated with CL 2d prior to injection of ODN 1826 (n=5). 
Controls were treated with CL and PBS, PBS and CpG or received injections of PBS only 
(n=5 per group). Data points represent individual animals; mean values (±SEM) are 
displayed. Data are representative of two similar independent experiments. (C) Quantitative 
real-time PCR analysis of hepatic iNOS expression 42h after infection. Samples from 
pretreated groups (n=5) or naïve controls (n=2) were pooled and analysed in technical 
triplicates. All expression levels are indicated as x-fold of the expression level in naïve mice. 
Bars indicate mean (+SEM). Data are representative of two independent experiments. 
*p<0.05; ** p<0.01.  
 
 
 Figure 6. Activation of TLR4 and -9 pathways independently impact clinical outcome 
of blood stage infection following pre-erythrocytic stage infection.  
(A) Flow-chart of experimental procedures. Mice were pre-stimulated with PBS (black), 
ODN 1826 (green) or the ODN 1826 control (cyan) polynucleotide, LPS (yellow) or poly I:C 
(red), infected with 10
4
 Pb sporozoites i.v., and analysed for clinical outcome. (B) Time to 
blood-stage infection after injection of 10
4 
Pb ANKA sporozoites 20h after stimulation with 
the respective reagent. Pre-patency was monitored by daily examination of Giemsa-stained 
blood films (n=6 per group). (C) Mean parasitaemia (±SEM) during the course of infection 
(n=6 per group). (D) Kaplan-Meier analysis of time from infection to the onset of ECM (n=6 
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Figure 7. Changes in serum cytokines/chemokine patterns correlate with protection 
against ECM. Serum samples were collected at the time of infection, 24h and 5 days post-
infection, and the concentrations of IFN-γ, MCP-1, TNF, IL-6, IL-10 and IL-12p70 were 
measured. Bars indicate median and range for each group at the individual time points. 
Changes over the course of infection within a group (day 0 versus day 1 and day 1 versus day 
5) as well as differences between PBS-treated and agonist-treated mice on day 0, 1, and 5 
after infection were assessed. Data are representative of two similar independent experiments. 
* p < 0.05; **p <0.01 (Mann-Whitney). 
 
Figure 8. Activation the TLR9 pathway impact clinical outcome of blood stage infection 
following infected red blood cell (iRBC) inoculation.  
(A) Flow-chart of experimental procedures. Mice were pre-stimulated with PBS (black) or 
ODN 1826 (green), inoculated with 10
4
 Pb iRBC i.v., and analysed for clinical outcome. (B) 
Time to detection of blood-stages after injection of 10
4 
Pb iRBC 20h after stimulation with 
the respective reagent. Pre-patency was monitored by daily examination of Giemsa-stained 
blood films (n=4 per group). (C) Mean parasitaemia (±SEM) during the course of infection 
(n=4 per group). (D) Kaplan-Meier analysis of time from infection to the onset of ECM (n=4 
per group). (E) Absence of ECM shown as the percentage of infected animals (n=4 per 
group). B-E, Data are representative of two similar independent experiments. *p<0.05; **p 
<0.01. 
